Parenteral Pharmaceutical formulation of sustained Release suspension, low dose and Ultra Low, hormone therapy for Climacteric syndrome

摘要

Refers to a Pharmaceutical composition for parenteral in suspension containing estradiol) suspended particles size of 1 to 100 micron particles; (b) progesterone of size of 1 to 100 micrometers; (c) a Surfactant such as Polysorbate 20, Polysorbate 80, Dioctyl Sulfosuccinate of SODIUM polyoxyethylene castor oil; (d) a isosmotico Agent such as Sodium Chloride, lactose,Tetralosa, mannitol, etc.; (e) a viscosante Agent such as Sodium CarboxyMethyl Cellulose, Polyethylene glycol polyethylene glycol 400, 300, among others; (f) one or more preservatives such as parabens, Propylparaben, phenol, thimerosal, among others. Sustained Release formulation is that the PH is 4 to 7 being useful for low-dose hormone replacement and Ultra Low